

ASTRAZENECA PLC
Form 6-K
December 04, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of (December 2018)

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82- _____

AstraZeneca PLC

INDEX TO EXHIBITS

1.
Director/PDMR Shareholding

4 December 2018 15:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

AstraZeneca PLC (the Company) announces that, on 3 December 2018, Marc Dunoyer, a person discharging managerial responsibilities (PDMR) exercised an option to purchase 544 of the Company's ordinary shares of \$0.25 each (Ordinary Shares) at a price of £33.07 per Ordinary Share, under the AstraZeneca PLC 2012 Savings Related Share Option Scheme (Sharesave).

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name
Marc Dunoyer

2 Reason for the notification

a) Position/status
Chief Financial Officer

b) Initial notification /Amendment
Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
AstraZeneca PLC

b) LEI
PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Description of the financial instrument, type of instrument		Ordinary Shares of US\$0.25 each in AstraZeneca PLC	
a)	Identification code	GB0009895292	
b)	Nature of the transaction	Exercise of option to purchase shares under the AstraZeneca PLC 2012 Savings Related Share Option Scheme (Sharesave)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£33.07	544
	Aggregated information	Not applicable - single transaction	
d)	- Aggregated volume		
	- Price		
e)	Date of the transaction	3 December 2018	
f)	Place of the transaction	Outside a trading venue	

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations

Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Gonzalo Viña	UK/Global	+44 203 749 5916
Jennifer Hursit	UK/Global	+44 7384 799 726
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	+1 302 885 2677

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Investor Relations

Thomas Kudsk Larsen		+44 203 749 5712
Henry Wheeler	Oncology	+44 203 749 5797
Christer Gruvris	Cardiovascular; Metabolism	+44 203 749 5711
Nick Stone	Respiratory; Renal	+44 203 749 5716
Josie Afolabi	Other	+44 203 749 5631
Craig Marks	Finance; Fixed Income	+44 7881 615 764
Jennifer Kretzmann	Retail Investors	+44 203 749 5824
US toll-free		+1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 04 December 2018

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary